These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22057359)

  • 1. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
    Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
    Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
    Jing C; Zheng Y; Feng Y; Cao X; Xu C
    Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
    Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
    Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
    Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
    Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic landscape and prognostic analysis of mantle cell lymphoma.
    Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
    Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
    Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
    Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of
    Carras S; Torroja A; Emadali A; Montaut E; Daguindau N; Tempescul A; Moreau A; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Barbieux S; Corm S; Banos A; Fouillet L; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouabdallah K; Amorim S; Garidi R; Voillat L; Joly B; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Burroni B; Callanan M; Le Gouill S; Gressin R
    Haematologica; 2024 Jun; 109(6):1857-1865. PubMed ID: 38031755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.
    Todorovic M; Balint B; Andjelic B; Stanisavljevic D; Kurtovic NK; Radisavljevic Z; Mihaljevic B
    Med Oncol; 2012 Sep; 29(3):2212-9. PubMed ID: 22170090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
    Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
    Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.
    Schneider S; Crescenzi B; Schneider M; Ascani S; Hartmann S; Hansmann ML; Falini B; Mecucci C; Tiacci E; Küppers R
    Int J Cancer; 2014 Feb; 134(4):832-43. PubMed ID: 23929122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
    Rodrigues JM; Hassan M; Freiburghaus C; Eskelund CW; Geisler C; Räty R; Kolstad A; Sundström C; Glimelius I; Grønbaek K; Kwiecinska A; Porwit A; Jerkeman M; Ek S
    Br J Haematol; 2020 Dec; 191(5):796-805. PubMed ID: 32748433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.